LEISA TAPIA: Open Payments
NPI 1164876579 · GREENSBORO, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$577 in 36 payments from 13 companies in 2025. Trend: 2023 $547 · 2024 $339 · 2025 $577
Food & beverage: $577
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 14 | $162 |
| ABBVIE INC. | 5 | $92 |
| Grifols USA, LLC | 3 | $74 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $45 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Abbott Laboratories | 2 | $36 |
| Amgen Inc. | 2 | $28 |
| AstraZeneca Pharmaceuticals LP | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $17 |
Products named: Wegovy, Prolastin-C Liquid, VRAYLAR, CAPLYTA, Ozempic, Auvelity, QULIPTA, FREESTYLE LIBRE 3.
Industry payments across NC — which companies pay providers there.
